Figure 8.
Figure 8. Analysis of cumulative survival of mice bearing Ramos lymphoma xenografts treated with PRIT using anti-CD20 1F5 (scFv)4SA fusion protein and 1F5 Ab-SA chemical conjugate. Groups of 10 mice bearing approximately 100 mm3Ramos tumor xenografts were treated as described in Figure 7 and analyzed for survival as a function of time. Treatment groups included mice treated with 1.4 (⋄) and 2.8 (○) nM of 1F5 (scFv)4SA, 1.4 nM of control CC49 (scFv)4SA (□), or 1.4 nM of 1F5 Ab-SA chemical conjugate (▪), followed 20 hours later by 5.8 nM CA, and 4 hours after that with (A) 800 or (B) 1200 μCi (29.6 or 44.4 MBq, respectively) 90Y-DOTA-biotin. Survival curves in this figure correspond to treatment groups designated in Figure 7.

Analysis of cumulative survival of mice bearing Ramos lymphoma xenografts treated with PRIT using anti-CD20 1F5 (scFv)4SA fusion protein and 1F5 Ab-SA chemical conjugate. Groups of 10 mice bearing approximately 100 mm3Ramos tumor xenografts were treated as described in Figure 7 and analyzed for survival as a function of time. Treatment groups included mice treated with 1.4 (⋄) and 2.8 (○) nM of 1F5 (scFv)4SA, 1.4 nM of control CC49 (scFv)4SA (□), or 1.4 nM of 1F5 Ab-SA chemical conjugate (▪), followed 20 hours later by 5.8 nM CA, and 4 hours after that with (A) 800 or (B) 1200 μCi (29.6 or 44.4 MBq, respectively) 90Y-DOTA-biotin. Survival curves in this figure correspond to treatment groups designated in Figure 7.

Close Modal

or Create an Account

Close Modal
Close Modal